Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191084 | 0.91 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL22771140 | 0.86 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL7508446 | 0.85 | TLR8 (0.62) | TLR8TLR7 | |
| SCHEMBL22790540 | 0.85 | TLR8 (0.72) | TLR8TLR7 | |
| SCHEMBL3032882 | 0.84 | TLR8 (0.61) | TLR8TLR7 | |
| SCHEMBL7505631 | 0.84 | TLR8 (0.63) | TLR8TLR7 | |
| SCHEMBL8179545 | 0.83 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL233010 | 0.83 | TLR8 (0.66) | TLR8TLR7 | |
| SCHEMBL22783803 | 0.82 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL11961332 | 0.82 | TLR8 (0.65) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20220347310-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4038053-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114585390-A | Aminobenzazepine compounds, immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3983082-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983080-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | Bolt Biotherapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2021067242-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067242-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020252294-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252254-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252254-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252294-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200390899-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | TLR8 3275/4885TLR7 1547/4885 |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | CCNB1, CCNB2, MUS81 | TLR8 3652/4885TLR7 4387/4885 |
| US-20200390899-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | TLR8 3275/4885TLR7 1547/4885 |
| US-20220347310-A1 | AMIDE-LINKED, AMINOBENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | AADAC, IGLV6-57, BCR | TLR8 535/4885TLR7 608/4885 |
| US-12570610-B2 | Macromolecule-supported aminobenzazepine compounds | BCL6, CLTB, MET | TLR8 2517/4885TLR7 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.